PMID- 2346519
OWN - NLM
STAT- MEDLINE
DCOM- 19900703
LR  - 20220310
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 33
IP  - 5
DP  - 1990 May
TI  - Measurement of increases in anti-double-stranded DNA antibody levels as a 
      predictor of disease exacerbation in systemic lupus erythematosus. A long-term, 
      prospective study.
PG  - 634-43
AB  - To evaluate the predictive power of changes in levels of antibodies to 
      double-stranded DNA (anti-dsDNA) as a predictor of disease exacerbations in 
      systemic lupus erythematosus (SLE), we performed a prospective study on 72 
      unselected patients with SLE (mean duration of study 18.5 months, range 6-35 
      months). Patients were seen at least once every 3 months, and disease activity 
      was scored according to a specific protocol. Plasma samples were obtained at 
      least once every month and were assessed for anti-dsDNA antibody (by the 
      Crithidia luciliae assay, an enzyme-linked immunosorbent assay [ELISA], and the 
      Farr assay) and for complement components C3 and C4. Twenty-seven of 33 disease 
      exacerbations observed during the study period were accompanied by a positive 
      test result for anti-dsDNA antibody (27 by the Farr assay, 19 by the C luciliae 
      assay, and 23 by the ELISA). Twenty-four of these exacerbations were preceded by 
      a significant increase in anti-dsDNA antibody levels (23 by the Farr assay, 12 by 
      the C luciliae assay, and 17 by the ELISA). The first observance of a significant 
      increase in anti-dsDNA antibody levels preceded the exacerbation by 8-10 weeks. 
      Significant increases in anti-dsDNA antibody levels not followed by an 
      exacerbation were observed in 5 cases by the Farr assay, in 7 cases by the C 
      luciliae assay, and in 3 cases by the ELISA; however, in 3 cases, 2 cases, and 1 
      case, respectively, these increases were followed by an increase in disease 
      activity that did not fulfill the criteria for an exacerbation. Serial 
      measurement of anti-dsDNA antibody levels was more sensitive for predicting 
      exacerbations than was measurement of C3 and/or C4 levels (P less than 0.03). 
      Serial assessment of anti-dsDNA antibody levels, especially by the Farr assay, is 
      a sensitive and reasonably specific method for predicting disease exacerbations 
      in SLE.
FAU - ter Borg, E J
AU  - ter Borg EJ
AD  - Department of Internal Medicine, University Hospital, Groningen, The Netherlands.
FAU - Horst, G
AU  - Horst G
FAU - Hummel, E J
AU  - Hummel EJ
FAU - Limburg, P C
AU  - Limburg PC
FAU - Kallenberg, C G
AU  - Kallenberg CG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Complement C3)
RN  - 0 (Complement C4)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibodies, Antinuclear/*analysis
MH  - Complement C3/analysis
MH  - Complement C4/analysis
MH  - DNA/*immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Forecasting
MH  - Humans
MH  - Lupus Erythematosus, Systemic/blood/*immunology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Time Factors
EDAT- 1990/05/01 00:00
MHDA- 1990/05/01 00:01
CRDT- 1990/05/01 00:00
PHST- 1990/05/01 00:00 [pubmed]
PHST- 1990/05/01 00:01 [medline]
PHST- 1990/05/01 00:00 [entrez]
AID - 10.1002/art.1780330505 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1990 May;33(5):634-43. doi: 10.1002/art.1780330505.